Most Read Articles
Stephen Padilla, 16 Dec 2019
Treatment with fludarabine, cytarabine and G-CSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or idarubicin (Ida) is associated with high remission rates among patients with newly diagnosed core binding factor acute myelogenous leukaemia (CBF-AML) with low induction mortalities, reports a study.
Stephen Padilla, 12 Dec 2019
Transitioning from bortezomib- to ixazomib-based induction is feasible, tolerable and effective in the treatment of community patients with newly diagnosed multiple myeloma (NDMM), according to a study presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).
Elaine Soliven, 17 Dec 2019
The addition of daratumumab to lenalidomide, bortezomib, and dexamethasone (RVd) significantly improves response rates and depth of response in patients with newly diagnosed multiple myeloma (NDMM) who are eligible for an autologous stem cell transplant (ASCT), according to updated results of the phase II GRIFFIN* study presented at ASH 2019.
5 days ago
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.

Dacomitinib triumphs over gefitinib as first-line treatment for advanced EGFR-positive NSCLC

Roshini Claire Anthony
12 Jun 2017
Professor Tony Mok

The second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) dacomitinib improved progression-free survival (PFS) by an additional 5 months compared with gefitinib in patients with EGFR-positive non-small cell lung cancer (NSCLC), according to results of the open-label, phase III ARCHER 1050* trial.

“Dacomitinib should be considered as a new treatment option for first-line management of patients with advanced EGFR-mutated NSCLC,” said study investigator Professor Tony Mok from the Chinese University of Hong Kong who presented the findings of the study at the annual meeting of the American Society of Clinical Oncology (ASCO 2017) held in Chicago, Illinois, US.

Four hundred and fifty two patients with advanced (stage IIIB to IV) NSCLC with EGFR-activating mutations, ECOG status 0–1 and no CNS metastasis who had not undergone prior systemic or TKI treatment were randomized to dacomitinib (45 mg QD, n=227, median age 62 years, 64.3 percent female, 74.9 percent Asian) or gefitinib (250 mg QD, n=225, median age 61 years, 55.6 percent female, 78.2 percent Asian).

Median PFS was higher with dacomitinib compared with gefitinib (14.7 vs 9.2 months, hazard ratio, 0.59, 95 percent confidence interval, 0.47–0.74; p<0.0001). [ASCO 2017, abstract LBA9007]

Duration of response also favoured the dacomitinib arm (median 14.8 vs 8.3 months; p<0.0001), while objective response rate was comparable between the dacomitinib and gefitinib arms (74.9 and 71.6 percent of patients, respectively; p=0.3883).

The most common grade 3 adverse events among patients on dacomitinib were dermatitis acneiform (13.7 percent), diarrhoea (8.4 percent), and paronychia (7.5 percent), while the most common grade 3 adverse event among patients on gefitinib was elevation of ALT levels (8.5 percent). There was one incident of grade 5 diarrhoea in patients on dacomitinib.

More patients on dacomitinib needed dose modification compared with gefitinib (66.1 percent vs 8.0 percent).

“We changed the treatment paradigm for EGFR-positive lung cancer a few years ago when targeted therapy replaced chemotherapy,” said Mok. “This study shows that dacomitinib may be an even more effective treatment for these patients. However, patients should be aware of the need to deal with potential side effects when making treatment decisions,” he said.

“Dacomitinib is superior to gefitinib in the front-line setting for EGFR L858R and del 19 mutation-positive NSCLC and represents a new additional standard of care, an alternative to afatinib,” said discussant Dr Sanjay Popat from The Royal Marsden Hospital in London, UK.

“However, toxicities are markedly different to gefitinib and this must be borne in mind in individual patient selection decisions,” said Popat, who highlighted that the use of dacomitinib may be limited by the results of the FLAURA** trial.

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 16 Dec 2019
Treatment with fludarabine, cytarabine and G-CSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or idarubicin (Ida) is associated with high remission rates among patients with newly diagnosed core binding factor acute myelogenous leukaemia (CBF-AML) with low induction mortalities, reports a study.
Stephen Padilla, 12 Dec 2019
Transitioning from bortezomib- to ixazomib-based induction is feasible, tolerable and effective in the treatment of community patients with newly diagnosed multiple myeloma (NDMM), according to a study presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).
Elaine Soliven, 17 Dec 2019
The addition of daratumumab to lenalidomide, bortezomib, and dexamethasone (RVd) significantly improves response rates and depth of response in patients with newly diagnosed multiple myeloma (NDMM) who are eligible for an autologous stem cell transplant (ASCT), according to updated results of the phase II GRIFFIN* study presented at ASH 2019.
5 days ago
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.